Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q33920652)
Watch
English
Neoral use in the renal transplant recipient
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
10814746
retrieved
30 July 2017
review article
1 reference
stated in
Europe PubMed Central
title
Neoral use in the renal transplant recipient
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
10814746
retrieved
30 July 2017
author name string
Belitsky P
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
10814746
retrieved
30 July 2017
language of work or name
English
0 references
publication date
1 May 2000
1 reference
stated in
Europe PubMed Central
PubMed ID
10814746
retrieved
30 July 2017
published in
Transplantation Proceedings
1 reference
stated in
Europe PubMed Central
PubMed ID
10814746
retrieved
30 July 2017
volume
32
1 reference
stated in
Europe PubMed Central
PubMed ID
10814746
retrieved
30 July 2017
issue
3A Suppl
1 reference
stated in
Europe PubMed Central
PubMed ID
10814746
retrieved
30 July 2017
page(s)
10S-19S
1 reference
stated in
Europe PubMed Central
PubMed ID
10814746
retrieved
30 July 2017
cites work
Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical pharmacokinetics of cyclosporin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neoral vs Sandimmun: interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. The U. K. Neoral Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Renal recipients of haploidentical living donors treated with Neoral or conventional cyclosporine: a comparative follow-up of 3 years
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neoral reduces the incidence of acute rejection after renal transplantation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cyclosporine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neoral without intravenous cyclosporine in liver transplantation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Induction of immunosuppression by microemulsion cyclosporine in liver transplantation.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Use of microemulsion form cyclosporine immediately after kidney transplantation without intravenous cyclosporine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lessons from the Neoral Global Database
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Trough cyclosporine concentration variability
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacokinetic drug interactions with cyclosporin (Part I).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacokinetic drug interactions with cyclosporin (Part II).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cyclosporine microemulsion formulation (Neoral) in transplantation: pharmacokinetic/pharmacodynamic relationships
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemical modification of rapamycin: the discovery of SDZ RAD.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
FTY720: a new immunosuppressive agent with novel mechanism(s) of action
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0041-1345(00)00860-5
1 reference
stated in
Europe PubMed Central
PubMed ID
10814746
retrieved
30 July 2017
PubMed ID
10814746
1 reference
stated in
Europe PubMed Central
PubMed ID
10814746
retrieved
30 July 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit